Performance of XXXX growth kinetics as an imaging biomarker for response assessment in colorectal liver metastases: correlation with FDG PET.

@entity5 @entity1 @entity16992
PURPOSE: To correlate RECIST, volumetric criteria, and @entity5 growth kinetics at multidetector-computed tomography with @entity5 metabolic activity at FDG PET in colorectal liver metastases (CRCLM) treated with bevacizumab-based chemotherapy. METHODS: Thirty-two CRCLM in 20 @entity1 treated with bevacizumab-based chemotherapy were evaluated. Pre- and post-treatment CT scans were used to calculate @entity16992 ( @entity16992 ), percentage change in the lesion's longest transaxial diameter (RECIST 1.1), and percentage change in the @entity5 volume. The accuracy of these parameters in predicting response based on standard uptake value analysis at FDG PET was assessed. Data were analyzed using Spearman's correlation, student's t, Mann-Whitney, Wilcoxon signed-rank, and Fisher's exact tests. RESULTS: According to FDG PET, 24/32 (75%) lesions were categorized as responders and 8/32 (25%) lesions as nonresponders. Based on @entity16992 , 26/32 (81.25%) lesions were classified as responders and 6/32 (18.75%) lesions as nonresponders. Response classification according to @entity16992 and FDG PET was concordant in 30/32 (93.75%) lesions, whereas RECIST 1.1 and volumetric criteria were concordant with FDG PET for 20/32 (62.5%) and 21/32 (65.63%) lesions, respectively. A strong association was found between @entity16992 and response based on FDG PET (odds ratio  =  127.4; 95% CI 5.54-2997; P  <  0.0001). CONCLUSIONS: Tumor growth kinetics may be an effective imaging biomarker for response evaluation in CRCLM.
